FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206934212> ?p ?o ?g. }

• W4206934212 endingPage "i366" @default.
• W4206934212 startingPage "i365" @default.
• W4206934212 abstract "Abstract Background Perianal complex fistulas in Crohn′s disease (CD) are difficult to treat by both surgical and conservative methods. Administration of allogenic, adipose-derived mesenchymal stem cells (darvadstrocel) was studied in a prospective randomised trial (PRS) with a success rate of more than, 50%. The aim of our study was prospectively evaluate results of commercial treatment of perianal fistulas in CD patients by darvadstrocel in Czech Republic. Methods We prospectively followed, 42 consecutive patients treated commercially by darvadstrocel since August, 2019 till August, 2021. Perianal CD activity index (PDAI) was recorded for all patients as well as well as AGA clinical fistula assesment. Complete healing was considered as: no secretion from the external opening, no infiltration perianally, no pain; treatment failure: clear perianal secretion, painful infiltration and / or the need for surgery; partial response: anamnestic mild secretion from one external opening, infiltration around the fistula without pain and without the need for surgical intervention. Results 42 prospectively monitored patients (17M /, 25F), average age, 42 years (range;, 21–70 years) underwent darvastrodstrocel treatment in, 2 Czech mesenchymal stem cell therapy centers (39 pp in NH Hospital, 3 in ISCARE center). Patients suffered from intestinal CD for an average of, 15.6 years (3–34 years), perianal CD for, 8.9 years (2–23 years) and underwent an average of, 7.5(3–24) minor perianal surgeries before the treatment., 38% (16) of patients had anorectal stenosis at the time of the treatment. Patients were treated on average, 25 months (6–84) by stable immunosuppressive and/or biologic therapy. Locally, it was complex fistulas, mostly high trans-sphincteric with, 1–3 external openings (EO) (78.6%;, 33 pp had, 1 EO) and with, 1–2 internal openings (IO) (14.3%;, 6 pp had, 2 IO). Patients were monitored for an average of, 10.5 months (range;, 4–26 months). Complete healing occurred in, 76% patients (32), partial response in, 11.9% (5pp) and treatment failure was in, 5 patients (11.9%). PDAI before MSC surgery was on average, 9.7 (3–13), 3 months after surgery, 3.2 (0–13) and, 6 months after surgery, 2.6 (0–13) in patients who have healed or healed partially. Conclusion The treatment was more successful in real life than in PRS, which may be due to the relatively short follow-up period. Another reason for better outcome could be proper selection of patients with long term stable conservative treatment, which demonstrates stable CD. In our conditions, this treatment is similarly effective as eradication of the fistula using AF, but it can also be used in difficult conditions such as anorectal stenosis or chronic changes in the rectal mucosa." @default.
• W4206934212 created "2022-01-26" @default.
• W4206934212 creator A5002251983 @default.
• W4206934212 creator A5015156475 @default.
• W4206934212 creator A5036973797 @default.
• W4206934212 creator A5052142834 @default.
• W4206934212 creator A5073186405 @default.
• W4206934212 date "2022-01-01" @default.
• W4206934212 modified "2023-09-25" @default.
• W4206934212 title "P356 Czech experience with treatment of Crohn′s disease perianal fistulas by allogenic mesenchymal stem cell" @default.
• W4206934212 doi "https://doi.org/10.1093/ecco-jcc/jjab232.483" @default.
• W4206934212 hasPublicationYear "2022" @default.
• W4206934212 type Work @default.
• W4206934212 citedByCount "0" @default.
• W4206934212 crossrefType "journal-article" @default.
• W4206934212 hasAuthorship W4206934212A5002251983 @default.
• W4206934212 hasAuthorship W4206934212A5015156475 @default.
• W4206934212 hasAuthorship W4206934212A5036973797 @default.
• W4206934212 hasAuthorship W4206934212A5052142834 @default.
• W4206934212 hasAuthorship W4206934212A5073186405 @default.
• W4206934212 hasBestOaLocation W42069342121 @default.
• W4206934212 hasConcept C141071460 @default.
• W4206934212 hasConcept C142724271 @default.
• W4206934212 hasConcept C188816634 @default.
• W4206934212 hasConcept C198826908 @default.
• W4206934212 hasConcept C2776341189 @default.
• W4206934212 hasConcept C2779797108 @default.
• W4206934212 hasConcept C2908621539 @default.
• W4206934212 hasConcept C71924100 @default.
• W4206934212 hasConceptScore W4206934212C141071460 @default.
• W4206934212 hasConceptScore W4206934212C142724271 @default.
• W4206934212 hasConceptScore W4206934212C188816634 @default.
• W4206934212 hasConceptScore W4206934212C198826908 @default.
• W4206934212 hasConceptScore W4206934212C2776341189 @default.
• W4206934212 hasConceptScore W4206934212C2779797108 @default.
• W4206934212 hasConceptScore W4206934212C2908621539 @default.
• W4206934212 hasConceptScore W4206934212C71924100 @default.
• W4206934212 hasIssue "Supplement_1" @default.
• W4206934212 hasLocation W42069342121 @default.
• W4206934212 hasOpenAccess W4206934212 @default.
• W4206934212 hasPrimaryLocation W42069342121 @default.
• W4206934212 hasRelatedWork W2023807646 @default.
• W4206934212 hasRelatedWork W2025624289 @default.
• W4206934212 hasRelatedWork W2364886158 @default.
• W4206934212 hasRelatedWork W2378585548 @default.
• W4206934212 hasRelatedWork W2415907950 @default.
• W4206934212 hasRelatedWork W3028991096 @default.
• W4206934212 hasRelatedWork W3031752428 @default.
• W4206934212 hasRelatedWork W3142047178 @default.
• W4206934212 hasRelatedWork W3213717952 @default.
• W4206934212 hasRelatedWork W4294904917 @default.
• W4206934212 hasVolume "16" @default.
• W4206934212 isParatext "false" @default.
• W4206934212 isRetracted "false" @default.
• W4206934212 workType "article" @default.